These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33757333)

  • 1. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment.
    Totan Y; Güler E; Gürağaç FB
    Curr Eye Res; 2016; 41(1):107-13. PubMed ID: 25610946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey.
    Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
    Rom J Ophthalmol; 2022; 66(4):304-309. PubMed ID: 36589330
    [No Abstract]   [Full Text] [Related]  

  • 13. PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA.
    Shah SU; Harless A; Bleau L; Maturi RK
    Retina; 2016 Oct; 36(10):1986-96. PubMed ID: 27124881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
    Maggio E; Sartore M; Attanasio M; Maraone G; Guerriero M; Polito A; Pertile G
    Am J Ophthalmol; 2018 Nov; 195():209-222. PubMed ID: 30098350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study.
    Iglicki M; Busch C; Zur D; Okada M; Mariussi M; Chhablani JK; Cebeci Z; Fraser-Bell S; Chaikitmongkol V; Couturier A; Giancipoli E; Lupidi M; Rodríguez-Valdés PJ; Rehak M; Fung AT; Goldstein M; Loewenstein A
    Retina; 2019 Jan; 39(1):44-51. PubMed ID: 29697589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment.
    Ceylan A; Dogan ME; Demircan A; Akar Y
    Int Ophthalmol; 2022 Nov; 42(11):3579-3588. PubMed ID: 35737210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
    Singh RP; Barakat MR; Ip MS; Wykoff CC; Eichenbaum DA; Joshi S; Warrow D; Sheth VS; Stefanickova J; Kim YS; He F; Cho GE; Wang Y; Emanuelli A
    JAMA Ophthalmol; 2023 Dec; 141(12):1152-1160. PubMed ID: 37971723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.